» Articles » PMID: 30602059

The Role of Neuro-immune Interactions in Cancer-related Fatigue: Biobehavioral Risk Factors and Mechanisms

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2019 Jan 3
PMID 30602059
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Fatigue is a common and distressing symptom in both patients with cancer and cancer survivors. There is substantial variation in the severity and persistence of cancer-related fatigue that may be driven by individual differences in host factors, including characteristics that predate the cancer experience as well as responses to cancer and its treatment. This review examines biobehavioral risk factors linked to fatigue and the mechanisms through which they influence fatigue across the cancer continuum, with a focus on neuro-immune processes. Among psychosocial risk factors, childhood adversity is a strong and consistent predictor of cancer-related fatigue; other risk factors include history of depression, catastrophizing, lack of physical activity, and sleep disturbance, with compelling preliminary evidence for loneliness and trait anxiety. Among biologic systems, initial work suggests that alterations in immune, neuroendocrine, and neural processes are associated with fatigue. The identification of key risk factors and underlying mechanisms is critical for the development and deployment of targeted interventions to reduce the burden of fatigue in the growing population of cancer survivors. Given the multidimensional nature of fatigue, interventions that influence multiple systems may be most effective.

Citing Articles

Prevalence and associated factors of cancer-related fatigue among adult patients with cancer attending oncology units: an institution-based cross-sectional study design in the Amhara region, Ethiopia, 2022.

Zeleke G, Worku W, Ayele D BMJ Public Health. 2025; 2(2):e000884.

PMID: 40018631 PMC: 11816097. DOI: 10.1136/bmjph-2023-000884.


Models of care and associated targeted implementation strategies for cancer survivorship support in Europe: a scoping review protocol.

Prue G, Czamanski-Cohen J, Kassianos A, Pilleron S, Ladas A, Akcakaya Can A BMJ Open. 2025; 15(2):e085456.

PMID: 39956597 PMC: 11831281. DOI: 10.1136/bmjopen-2024-085456.


Quality of life after idiopathic multicentric Castleman disease in China: a cross-sectional, multi-center survey of patient reported outcome and caregiver reported outcome.

Chen J, Zhang M, Gao Y, Zhang L, Li J Orphanet J Rare Dis. 2024; 19(1):469.

PMID: 39702341 PMC: 11660598. DOI: 10.1186/s13023-024-03450-0.


Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation.

Chen M, Zhou S, He X, Wen H Br J Cancer. 2024; 132(3):283-294.

PMID: 39676131 PMC: 11791036. DOI: 10.1038/s41416-024-02922-1.


Symptom improvements and adverse effects with Reishi mushroom use: A Cross-Sectional survey of cancer patients.

Li X, Sun L, Chimonas S, Li S, Feng P, Yang Y Integr Med Res. 2024; 13(4):101089.

PMID: 39635077 PMC: 11614793. DOI: 10.1016/j.imr.2024.101089.


References
1.
Broeckel J, Jacobsen P, Horton J, Balducci L, Lyman G . Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998; 16(5):1689-96. DOI: 10.1200/JCO.1998.16.5.1689. View

2.
Han T, Felger J, Lee A, Mister D, Miller A, Torres M . Association of childhood trauma with fatigue, depression, stress, and inflammation in breast cancer patients undergoing radiotherapy. Psychooncology. 2015; 25(2):187-93. PMC: 4973143. DOI: 10.1002/pon.3831. View

3.
Collado-Hidalgo A, Bower J, Ganz P, Cole S, Irwin M . Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006; 12(9):2759-66. DOI: 10.1158/1078-0432.CCR-05-2398. View

4.
Bower J, Irwin M . Mind-body therapies and control of inflammatory biology: A descriptive review. Brain Behav Immun. 2015; 51:1-11. PMC: 4679419. DOI: 10.1016/j.bbi.2015.06.012. View

5.
Andrykowski M, Donovan K, Laronga C, Jacobsen P . Prevalence, predictors, and characteristics of off-treatment fatigue in breast cancer survivors. Cancer. 2010; 116(24):5740-8. PMC: 4048855. DOI: 10.1002/cncr.25294. View